Real-World Evaluation of Trastuzumab Emtansine Biosimilar in Early-Stage HER2-Positive Breast Cancer: Results from a Single-Center Retrospective Study in India
Archives of Breast Cancer · 22.04.2026 · 13 (2) · 182-189
DOI: 10.32768/abc.2906718345-529 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Breast Cancer, online erschienen am 22.04.2026. Verfasst von Kaushal Kaushal und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Trastuzumab emtansine (T-DM1), an antibody-drug conjugate targeting HER2, is an established adjuvant therapy for residual invasive HER2-positive breast cancer after neoadjuvant treatment. Real-world evidence on trastuzumab emtansine biosimilars in early-stage disease is limited. This study evaluated invasive disease-free survival (iDFS) and safety outcomes with a trastuzumab emtansine biosimilar in routine practice.
Methods
This retrospective, single-center observational study include 24 women with stage II and III HER2-positive breast cancer who received adjuvant trastuzumab emtansine biosimilar (3.6 mg/kg every 21 days) after neoadjuvant chemotherapy and surgery. The primary endpoint was iDFS; secondary endpoints were relapse patterns and treatment-emergent adverse events.
Results
Median age was 60.3 years; 83.3% were postmenopausal. At diagnosis, 20.8% had stage II and 79.2% had stage III disease. With a median follow-up of 14 months, 5 iDFS events occurred and no deaths were reported. The 12-month iDFS rate was 79.2%. Relapse occurred in 20.8% (5/24 patients); sites of recurrence included bone (n=2, 40%), liver (n=2, 40%), and brain (n=1, 20%), reflecting a predominantly skeletal and visceral, distant metastatic pattern. Common adverse events were thrombocytopenia (95.8%), neutropenia (79.2%), and anemia (41.7%), predominantly grade 1–2. Left ventricular ejection fraction declined to
Zitieren
APA
Kaushal, K., Thummar, V., & Mehta, P. (2026). Real-World Evaluation of Trastuzumab Emtansine Biosimilar in Early-Stage HER2-Positive Breast Cancer: Results from a Single-Center Retrospective Study in India. Archives of Breast Cancer, 13(2), 182-189. https://doi.org/10.32768/abc.2906718345-529
Vancouver
Kaushal K, Thummar V, Mehta P. Real-World Evaluation of Trastuzumab Emtansine Biosimilar in Early-Stage HER2-Positive Breast Cancer: Results from a Single-Center Retrospective Study in India. Archives of Breast Cancer. 2026;13(2):182-189. doi:10.32768/abc.2906718345-529
BibTeX
@article{Kaushal2026,
author = {Kaushal, Kaushal and Thummar, Vipulkumar and Mehta, Priya},
title = {Real-World Evaluation of Trastuzumab Emtansine Biosimilar in Early-Stage HER2-Positive Breast Cancer: Results from a Single-Center Retrospective Study in India},
journal = {Archives of Breast Cancer},
year = {2026},
volume = {13},
number = {2},
pages = {182--189},
doi = {10.32768/abc.2906718345-529}
}
EUVIMED